Drug Development

HEALTH CARE POLICY 1 Credit CME Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies JAMA Internal Medicine

CLINICAL PHARMACY AND PHARMACOLOGY 12m 50s 0.25 Credit CME Update on Dexamethasone for the Treatment of COVID-19 JAMA

INFECTIOUS DISEASES 40m 35s 0.5 Credit CME COVID-19 and the FDA JAMA

DRUG DEVELOPMENT 1 Credit CME Missed Opportunities on Emergency Remdesivir Use JAMA

CLINICAL PHARMACY AND PHARMACOLOGY 36m 28s 0.5 Credit CME Remdesivir and Dexamethasone for the Treatment of COVID-19 JAMA

INFECTIOUS DISEASES 5m 46s Monoclonal Antibodies for Coronavirus JAMA

DRUG DEVELOPMENT 1 Credit CME The Equitable Distribution of COVID-19 Therapeutics and Vaccines JAMA

CORONAVIRUS (COVID19) 1 Credit CME Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An Unprecedented Partnership for Unprecedented Times JAMA

INFECTIOUS DISEASES 37m 56s 0.5 Credit CME The NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Initiative JAMA

INFECTIOUS DISEASES 39m 37s 0.5 Credit CME The NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Initiative JAMA

ADOLESCENT MEDICINE 1 Credit CME Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity JAMA Network Open

DRUG DEVELOPMENT 1 Credit CME Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies JAMA

DRUG DEVELOPMENT 1 Credit CME Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 JAMA

CLINICAL PHARMACY AND PHARMACOLOGY 1 Credit CME FDA Approval and Regulation of Pharmaceuticals, 1983-2018 JAMA

ONCOLOGY 13m 42s JAMA Guide to Statistics and Methods JAMA

ONCOLOGY 1 Credit CME A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review JAMA Oncology

RADIOLOGY 1 Credit CME Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial JAMA Psychiatry

CLINICAL PHARMACY AND PHARMACOLOGY 14m 36s Cost of Developing a Single Cancer Drug JAMA Internal Medicine

LAW AND MEDICINE 27m 51s 0.5 Credit CME Are they safe? Drugs and devices receiving accelerated approval by the FDA JAMA

ONCOLOGY 5m 14s Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012 JAMA